JScreen announces fifth annual Jewish Genetic Screening Awareness Week

It is taking place from Feb. 4 through Feb. 10.

JScreen. Credit: Courtesy.
JScreen. Credit: Courtesy.

JScreen, a national nonprofit public-health initiative dedicated to preventing genetic diseases, announces the fifth annual Jewish Genetic Screening Awareness Week (JGSAW), which takes place from Feb. 4 through Feb. 10.

Initiated in 2020 with organizational partners across the nation, JGSAW serves to educate the community about the importance of screening for genetic diseases and to raise awareness about testing resources. Jewish Genetic Screening Awareness Week was officially recognized in the morning orders by the Georgia State Legislature according to the Proclamation Declaring Jewish Genetic Screening Awareness Week.

The goal of JGSAW is to help ensure the health of individuals and their future families through education and genetic testing.

Dr. Janis Finer of Tulsa, Okla., knows the importance of getting tested. While she had no known family history of breast or ovarian cancer, her daughter, Dina Finer Gluck of Nashville, Tenn., was offered testing as part of a routine doctor’s visit. They were shocked when Dina tested positive for a mutation in a BRCA gene at the age of 34. A BRCA mutation puts an individual at greater risk for breast, ovarian, pancreatic and prostate cancer. Men and women with Ashkenazi Jewish ancestry are at 10 times greater risk of carrying a mutation in a BRCA gene than the general population, even without a family history of related cancers.

The good news is there are actionable steps a person can take if they test positive for certain cancer gene mutations, including BRCA. “It’s a blessing to know what you can do when you face a high risk for cancer but don’t actually have it,” says Dina. Although she chose to undergo risk-reducing surgery with a double mastectomy, other women who test positive for a BRCA mutation may choose additional surveillance with breast MRIs in addition to mammograms. “The BRCA genes were very low on my list of concerns, but after I found I was BRCA positive, I chose to have surgery, as I found I had an up to 80% lifetime risk of breast cancer and a 40% to 60% chance of ovarian cancer,” she explains. “I will thrive despite my genetic predisposition and so can you.”

Now in its 11th year, JScreen makes genetic testing simple, accessible, and affordable with its easy-to-use at-home saliva kits. Many people are familiar with JScreen’s reproductive testing, which gives prospective parents a deep understanding of their risk of having a child with a genetic disease.  If a couple’s risk is elevated, genetic counselors privately address their results by phone or video teleconference and provide options to help them plan for the health of their future children. JScreen’s cancer genetic test is a newer addition and alerts a person to their risk for hereditary cancer so they can be proactive about their own health. By providing convenient at-home access to cutting-edge genetic testing technology, patient education and genetic counseling services, JScreen strives to prevent devastating genetic diseases and ensure a healthy future for all.

“Preventing genetic diseases and hereditary cancer is our mission. We want to ensure generations of healthy children and adults. ‘Get Tested’ is our message because the more people we educate and test, the closer we are to achieving our goal,” says Karen Arnovitz Grinzaid, executive director of JScreen.

To learn more and register for testing, see: www.jscreen.org

You have read 3 articles this month.
Register to receive full access to JNS.
About & contact The Publisher
JScreen is a national nonprofit public health initiative dedicated to preventing genetic diseases. Headquartered in Atlanta at Emory University School of Medicine, the JScreen initiative provides convenient at-home access to cutting-edge genetic testing technology, patient education and genetic counseling services. JScreen believes the combination of education, access to premier gene screening technologies and personalized, confidential support are the keys to preventing these devastating diseases.
Releases published on the JNS Wire are communicated and paid for by third parties. Jewish News Syndicate, and any of its distribution partners, take zero responsibility for the accuracy of any content published in any press release. All the statements, opinions, figures in text or multimedia including photos or videos included in each release are presented solely by the sponsoring organization, and in no way reflect the views or recommendation of Jewish News Syndicate or any of its partners. If you believe any of the content in a release published on JNS Wire is offensive or abusive, please report a release.
Thank you. You are a loyal JNS Reader.
You have read more than 10 articles this month.
Please register for full access to continue reading and post comments.
Never miss a thing
Get the best stories faster with JNS breaking news updates